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Abstract: Type I disorders of glycosylation (CDG), the most frequent of which is phosphomannomutase
2 (PMM2-CDG), are a group of diseases causing the incomplete N-glycosylation of proteins.
PMM2-CDG is an autosomal recessive disease with a large phenotypic spectrum, and is associated
with mutations in the PMM2 gene. The biochemical analysis of mutants does not allow a precise
genotype–phenotype correlation for PMM2-CDG. PMM2 is very tolerant to missense and loss of
function mutations, suggesting that a partial deficiency of activity might be beneficial under certain
circumstances. The patient phenotype might be influenced by variants in other genes associated with
the type I disorders of glycosylation in the general population.
Keywords: disorder of glycosylation; variant analysis; clinical informatics; modifier genes
1. Introduction
PMM2-CDG is the most common disorder of glycosylation (CDG) and is caused by mutations
in the PMM2 gene, impairing the activity of phosphomannomutase 2 (PMM2). CDGs affecting
N-glycosylation can be subdivided into two groups, type I defects that involve synthesis and transfer
of lipid-linked oligosaccharides (LLOs) and type II defects that impair the modification process of
protein-bound oligosaccharides. PMM2-CDG, also known as CDG-Ia (or Jaeken syndrome), belongs
to the first group.
The first step towards protein N-glycosylation requires the interconversion of mannose
6-phosphate (M6P) into mannose 1-phosphate (M1P). In humans, there are two paralogous enzymes,
PMM1 and PMM2 [1], both requiring glucose 1,6 bisphosphate (G16) or mannose 1,6 bisphosphate
(M16) as an activator. Both enzymes are mutases, but PMM1 has phosphatase activity too (i.e., it is
able to hydrolyze G16). The role of PMM1 might be critical, because it can either support PMM2 by
contributing to M6P isomerization or counteract PMM2 by hydrolyzing the activator G16 [2,3]. M1P is
a precursor to GDP-mannose, which is necessary for the synthesis of dolichol phosphate mannose and
lipid-linked oligosaccharide (LLO). The synthesis of LLO requires the activity of several enzymes in a
multistep process that results in the addition of two N-acetyl glucosamines, nine mannoses, and three
glucoses. The oligosaccharyltransferase, which transfers the oligosaccharide from LLO to the accepting
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protein, has a reduced affinity for immature LLOs [4] and, as a consequence, the N-glycosylated
proteins are less abundant, when the pathway leading to the LLO synthesis is defective.
CDG-I can be diagnosed by the identification of hypoglycosylated liver-derived serum
glycoproteins and liver proteins [5,6], in particular, transferrin [4]. However, as this test is not specific,
a molecular diagnosis of PMM2-CDG through the PMM2 gene sequencing is needed. More than 110
pathological mutations have been associated with PMM2-CDG. Usually, patients have compound
heterozygotes with one inactivating mutation, Arg141His being by far the most common allele [7,8],
and one hypomorphic mutation. More rarely, they carry two different hypomorphic mutations in
heterozygosity or one hypomorphic mutation in homozygosity. Correlating the phenotype to genotype
is made difficult by the existence of a large number of mutations and a relatively small number
of patients [9]. The study of the properties of single PMM2 mutants [10–13] or, in rare cases, of
heterodimeric PMM2 mutants [14], after their expression in E. coli or in human fibroblasts, has been
used to determine their biochemical phenotype and to attempt a correlation with the clinical phenotype.
It is worth remembering that the enzyme is an obligate dimer and studying activity/stability of single
mutant homodimers is a shortcoming of the analysis [14]. Here, we describe the study of the mutants
Val129Met and Val231Met and compare the properties of the purified proteins with the phenotype
of the patients to illustrate the limitation of this method. We show that PMM2 is very tolerant to
missense mutations. The lack of correlation between the biochemical and clinical phenotypes might be
explained, in part, by considering that the partial loss of PMM2 activity is only one of the determinants,
and that other gene variants contribute to the severity of PMM2-CDG. We propose that other partially
deficient genes act as modifiers of PMM2-CDG and present a list of candidate variants.
2. Results
2.1. Clinical Phenotypes and “Biochemical” Phenotypes of Phosphomannomutase 2 (PMM2) Mutants
Do Not Correlate
To predict the severity of PMM2-CDG, one could measure the stability and residual activity of
the mutant proteins expressed in E. coli or in eukaryotic cells [10–14]. We followed this approach
for two mutants that present the same conservative substitution, Val to Met. Val129Met and
Val231Met are among the most frequent mutations and have been encountered in several countries.
The genotypes Val129Met/Arg141His and Val231Met/Arg141His including these mutant alleles have
been associated with severe phenotypes in unrelated families, in seven and eighteen reported cases,
respectively [11,15–19].
We measured not only the catalytic parameters, but also the long-term stability and melting
temperature of these mutant proteins by thermal shift assay (Table 1), as it cannot be excluded that the
role played by PMM2 in the cell does not require enzymatic activity. The melting temperatures are
related to the thermodynamic stability of proteins [20], whereas the long-term measurements consent
to compare the stability of different mutations at the same temperature.
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Table 1. Biochemical phenotype of some phosphomannomutase 2 (PMM2) variants. M1P: mannose 1-phosphate.
















100 18 10 µM M16 1.1 200 µM M1P 100 - [10]
100 16.0 ± 1.5 3 µM M16 5.4 ± 0.6 * * 200 µM M1P
100 **
100 (in the presence of
200 µM G16) **






24.5 45 50 µM M16 4.9 200 µM M1P ~60 - [10]
29 11.8 ± 1.0 3 µM M16 nd nd ~95 (37 ◦C) 45.0 ± 0.8 *** [13]*** [21]
Val29Met
50 21 10 µM M16 1.1 200 µM M1P ~55 - [10]
89 33.0 ± 3.9 3 µM M16 3.7 ± 0.5 200 µM M1P
83
100 (in the presence of
200 µM G16)
48.1 ± 1.0 this paper
Val231Met
38.5 18 10 µM M16 1.1 200 µM M1P ~20 - [10]
20 6.9 ± 1.1 3 µM M16 5.9 ± 1.1 200 µM M1P
23
76 (in the presence of
200 µM G16)
40.0 ± 3.0 this paper
nd: not determined; *, **, *** indicate the source of the data.
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For comparison, we added the data for wild-type (wt)-PMM2 and Phe119Leu, which are
well-characterized pathological mutations [22]. Val129Met retains more than 50% activity under
our experimental conditions and is slightly less stable than wild-type, whereas Val231Met has residual
activity and its stability is lower than that of a well-founded severe mutation, Phe119Leu [22]. Our
data on the relative activity and stability of Val129Met and Val231Met are in line with those reported
by van Schaftingen and collaborators [10].
In Figure 1, we show the model of PMM2 in the closed conformation induced by G16 binding [21].
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nucleofile transferring the phosphate from the O6 to O1 of mannose. Val231 is invariant in the 
PMM2 as well as in PMM1 ortologues, while Val129M is not conserved [23]. 
Therefore, although the two mutations affect the PMM2 activity in a very different manner, the 
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rare (MAF < 0.1%) variants per gene and separated them into synonymous, missense, and loss of 
function mutations (stop-gained and essential splice sites) [24]. From the original file we extracted 
the genes that were annotated in UniProt with the keyword “disease” [24]. From this set we 
subtracted the genes that are associated with autosomal dominant diseases [25], obtaining 3125 
instances on which the analysis was carried out. 
We observed that the ratio between the number of observed and predicted missense mutations 
for PMM2 is abnormally high for a gene associated with a human disease, even excluding the genes 
with autosomal dominant inheritance (Figure 2). 
Figure 1. Val129 and Val231 in the structure of phosphomannomutase2. Phosphomannomutase 2
(PMM2) (single chain) is represented as cartoons. Asp12, Val129, and Val231 are shown as sticks in
magenta, blue, or red, respectively. Glucose-1,6-bisphosphate (G16) is represented by sticks and is
colored by atom types. Mg2+ is represented by a green sphere. Different orientations of the same
molecule are shown.
Neither Val129 nor Val231 are in contact with the ligand and hence they do not belong to the active
site. Yet, Val231 is closer than Val129 to the catalytic center of PMM2, Asp12, which is the nucleofile
transferring the phosphate from the O6 to O1 of mannose. Val231 is invariant in the PMM2 as well as
in PMM1 ortologues, while Val129M is not conserved [23].
Therefore, although the two mutations affect the PMM2 activity in a very different manner,
the phenotype of the patients with the Arg141His/Val129Met or Arg141His/Val231Met genotypes is
similarly severe.
2.2. Missense and Loss of Function Mutations in PMM2 Are Unexpectedly Frequent in the General Population
With a final data set spanning more than 60,000 individuals, the Exome Aggregation Consortium
(ExAC) provides a unique possibility for evaluating the occurrence of PMM2 variants in the general
population [24]. The team of ExAC provided the number of observed and expected rare (MAF < 0.1%)
variants per gene and separated them into synonymous, missense, and loss of function mutations
(stop-gained and essential splice sites) [24]. From the original file we extracted the genes that were
annotated in UniProt with the keyword “disease” [24]. From this set we subtracted the genes that are
associated with autosomal dominant diseases [25], obtaining 3125 instances on which the analysis was
carried out.
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We observed that the ratio between the number of observed and predicted missense mutations
for PMM2 is abnormally high for a gene associated with a human disease, even excluding the genes
with autosomal dominant inheritance (Figure 2).
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Figure 2. Observed versus expected variants for disease genes. Box-plots are drawn for the ratios
between the number of observed and predicted variants in the general population for disease genes.
Each dot represents a gene, the red dot is PMM2, yellow dots are the other genes associated with
glycosylation (CDG)-I, and the blue dots are the genes associated with CDG-II. The medians are
indicated by thick black lines; the lower and upper quartiles, representing observations outside the
25–75 percentile ranges, are indicated by dashed black lines; and the relative minimum and relative
maximum values are indicated by dashed red lines.
As can be noticed in Figure 2, a high ratio of observed versus predicted missense mutations
is peculiar for PMM2 and is not a common feature among the CDG associated genes. The ratio of
observed versus predicted loss of function mutations, for PMM2, is above the median as well.
In supplementary File S1, we provide the list of non-singleton missense mutations in the PMM2
extracted from ExAC [26] with the occurrence of the mutation in the active site and reference in HGMD
(when available) [27]. In supplementary File S2, we provide annotations concerning the deleteriousness
of the mutations obtained running 12 different predictors. We run PolyPhen2 [28], SIFT [29],
LRT [30], MutationAssessor [31], PROVEAN [32], metaSVM [33], metaLR [33], MutationTaster [34],
FATHMM [35], and fathmm-MKL coding [36], which provide a discrete classification of variants
(classifying predictors) as well as CADD [37], which provides raw scores and scaled scores (CADD
phred score). CADD is not limited to missense variants, and takes into account not only the effect on
the protein, but also other features such as the proximity of the nucleotide change to an exon-intron
junction, and so on. The outputs of the classifying predictors differ; SIFT and PolyPhen2 appear
to have the least tendency to overesti ation and provide the smallest ratio of deleterious mutation
(supplementary File S2).
Excluding singletons, which are mutation observed in a single pe son, 56 miss ns m tations
were observed, 50% of which are predicted as deleterious according to PolyPhen2 [28], SIFT [29], and
CADD [37]. No loss of unction or misse se mutation th t i predict as delet rious by PolyPhen2 has
ever been observed in homozygosity in the general population. The CADD sc led scores ( hred score)
for the PMM2 n n-singleton variants bserved in the gen ral population, are reported in Figure 3.
Each dot represents a variant, the green dots are the variants that are predicted as benign by PolyPhen2,
the orange dots are those predicted as probably damaging by PolyPhen2, the yellow dots are possibly
damaging by PolyPhen2, and the red dots are those occurring in the active site. Although the CADD
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does not classify variants, it was suggested that 15 be used as a cut-off value to distinguish the
deleterious missense mutations. The CADD and Polyphen2 agree substantially, and the raw scores
correlate with an r value of 0.80 and a p value < 0.0001 (data in supplementary File S2).
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Figure 3. Distribution of CADD scaled scores and PolyPhen2 deleteriousness predictions for PMM2
frequent variants. The medians are indicated by thick black lines; the lower and upper quartiles,
representing observations outside the 25–75 percentile ranges, are indicated by dashed black lines; and
the relative minimum and relative maximum values are indicated by dashed red lines.
Missense mutations have been observed in PMM2 with a relatively low frequency, excluding
Glu197Ala, which was found in approximately 2% of the general population in all ethnic groups, with
the exception of Eastern Asians (supplementary File S1). This variant has been observed in association
with Arg141His in patients with the moderate phenotype [17,38]. The effect of this mutation on the
protein expressed in E. coli is mild [11,39].
2.3. Genes Involved in Congenital Disorders of Glycosylation I (CDG-I) Pathologies Have Frequent Variants in
the General Population
The severity of PMM2-CDG could depend on the genetic background. Indeed this hypothesis
could explain many reports concerning the lack of correlation between the genotype and
phenotype [9,40,41]. Mutations affecting the other genes involv d in the type I CDGs could act
as modifiers of the PMM2-CDG phenotype. We ex racted th se mutations f om ExAC and found that
many of them are relatively frequent and some of the are predicted as deleterious by PolyPhen2,
which is the tool most co only used for variant annotation, as well as by other predictors,
such as SIFT [29], LRT [30], MutationAssessor [31], PROVEAN [32], metaSVM [33], metaLR [33],
MutationTaster [34], FATHMM [35], fathmm-MKL coding [36], and CADD [37]. In supplementary
File S2, we provide the complete list of deleteriousness predictions, and in supplementary File S3, we
provide all of the data extracted from ExAC for the frequent mutations in type I CDG genes (allelic
frequency >0.001) and the reference in HGMD (when available) [27]. In Table 2, we provide the list of
potentially damaging mutations according to PolyPhen2 and CA D, with the accordance obtained
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with eleven different classifiers (number of non-benign prediction) and with their allelic frequency.
Altogether, the allelic frequency of deleterious mutations in the CDG-I genes, excluding PMM2, is
above 0.30. The most frequent deleterious variants are Ala229Thr in MPDU1, Ile393Val in ALG12, and
Arg268Gln in ALG8 (Table 2). All of these variants are panethnically distributed (supplementary File
S3).
Table 2. Frequent deleterious variants in type I disorders of glycosylation other than
PMM2-glycosylation (CDG).
Gene Mutation Accordance Among Classifiers CADD Scaled Scores Allele Frequency
ALG6 p.Leu453Val 10/11 23.6 0.012
ALG3 p.Val362Ile 7/11 25.5 0.001
MPDU1
p.Ala229Thr 3/11 20.9 0.154
p.Gly225Ser 4/11 24.1 0.010
ALG12 p.Ile393Val 7/11 23.4 0.112
ALG8 p.Arg268Gln 11/11 35 0.014
ALG2 p.Pro56Leu 10/11 24.2 0.001
ALG1
p.Thr64Asn 7/11 24.7 0.003
p.Ala3Asp 3/11 22.6 0.001
ALG9 p.Ser255Leu 5/11 23.4 0.003
RFT1
p.Ala185Thr 8/11 26.8 0.017
p.Ser16Cys 10/11 23.9 0.001
SRD5A3 p.His309Asp 7/11 15.91 0.004
DDOST
p.Arg315Gln 6/11 29.9 0.003
p.Thr400Ile 10/11 32 0.001
3. Discussion
A number of missense mutations higher than that expected for a gene associated with a recessive
disease is observed in PMM2. Half of them are predicted as deleterious. This finding experimentally
supports the hypothesis that has been put forward by Freeze [42], that many different mutations have
arisen in PMM2 and have not been negatively selected, possibly because a reduced mannomutase
activity has a beneficial role under certain conditions. For other genes with a high ratio between the
observed and predicted missense mutation, a protective effect has been reported. A few examples
will be cited, namely: CD36, which is responsible for Platelet glycoprotein IV deficiency, but is
protective against atherosclerosis [43]; MTUS1, which associated to Hepatocellular carcinoma, but
plays a protective role against inflammation [44]; and DAOA, which is associated with Schizophrenia,
but is related to better cognitive performance [45].
People carrying one wild-type PMM2 allele and one inactivating mutation on the other allele are
asymptomatic. Hence, it is accepted that a 50% PMM2 activity should be sufficient [46]. When both
alleles carry a mutation, the residual activity can drop below the safety threshold, and the symptoms
of the PMM2-CDG can be manifested in a severe, moderate, or mild form.
Predicting the severity of the disease is difficult, even when the mutation present in each allele
is known. A thorough biochemical characterization of the purified PMM2 mutants can possibly
distinguish between the extreme ends of the phenotype, but the genetic background should be taken
into account for the grading diagnosis. Actually, it has been observed that the presence of the variant
Phe304Ser in the gene ALG6 can worsen the PMM2-CDG phenotype [47,48]. Phe304Ser_ALG6 was
also found in the homozygous state in a severe CDG-I associated with dehydrodolichol diphosphate
synthase deficiency [49]. Phe304Ser_ALG6 is indeed one the most frequent variants observed
in the general population, both in heterozygosity and homozygosity [26]. Although it is not a
disease variant [50], Phe304Ser_ALG6 is less fit than the wild-type in restoring the glycosylation
of glycoprotein carboxypeptidase Y when introduced into a yeast strain deleted for ALG6. We showed
that Phe304Ser_ALG6 is not the only candidate modifier. In fact, the data reported in ExAC for the
genes associated with CDG-I reveal that other missense mutations are relatively frequent in the general
Int. J. Mol. Sci. 2018, 19, 2218 8 of 12
population, some of which are probably deleterious. We do not yet know if these variants can modulate
PMM2-CDG, but this is certainly something that should be assessed in patients.
4. Materials and Methods
DEAE-Sepharose ff and Superdex-75 were purchased from GE Healthcare Life Sciences, Milan,
Italy. Phosphoglucose isomerase from rabbit muscle, phosphomannose isomerase from E. coli, glucose
6-phosphate dehydrogenase from baker’s yeast (S. cerevisiae), phosphoglucomutase from rabbit
muscle, α-D(+)Mannose 1-phosphate sodium salt hydrate, and β-Nicotinamide adenine dinucleotide
phosphate sodium salt, were purchased from Sigma-Aldrich, Milan, Italy. Sypro Orange was from
Invitrogen Molecular Probes, Monza, Italy. Mannose-1,6-bisphosphate was synthesized and purified,
as described [3]. All of the other reagents were of analytical grade.
4.1. Protein Expression and Purification
Val129Met-PMM2 and Val231Met-PMM2 were expressed in E. coli (BL21[DE3] strain, using
the Pet22b+ expression vector) and purified following a protocol similar to that applied for the
wild-type PMM2 [13,14,51]. The bacteria were grown at 37 ◦C in an LB broth in the presence of
ampicillin 0.2 mg/mL and isopropyl 1-thio-β-D-galactopyranoside; 0.4 mM was added when the
optical density was 0.5 in order to induce the expression of the proteins. The culture was prolonged
for 4 h, then the cells were harvested; washed with PBS; suspended in Tris 50 mM, pH 7.5 containing
2-mercaptoethanol 1 mM, EDTA 5 mM, and phenylmethylsulfonyl fluoride 1 mM; and lysed with
lysozyme 1 mg/mL. MgCl2 10 mM was added before adding Deoxyribonuclease I 0.005 mg/mL.
The clear homogenate was recovered and a salting-out step was realized by adding ammonium
sulfate to a 60% saturation. The recovered material was dissolved and dialyzed (in Hepes 50 mM,
pH 7.1 containing 2-mercaptoethanol 1 mM), then loaded onto a DEAE-Sepharose Fast Flow column
equilibrated with the same buffer. The pass-through was collected. A final fractionation step on
a Superdex 75 column (equilibrated in Hepes 20 mM, MgCl2 1 mM, NaCl 150 mM, pH 7.5) was
conducted. The active fractions judged pure by SDS-PAGE were pooled and concentrated.
4.2. Enzymatic Assays
Human phosphomannomutases catalysed the conversion of glucose-1 phosphate (G1P) into
glucose 6-phosphate (G6P), as well as that of M1P into M6P [3,51].
The phosphomannomutase activity (i.e., isomerization of M1P in the presence of M16) was
measured spectrophometrically at 340 nm, at 32 ◦C, in Hepes 20 mM, pH 7.5 containing MgCl2 1 mM,
NaCl 150 mM, NADP+ 0.25 mM, BSA 0.1 mg/mL, glucose-6-phosphate dehydrogenase 0.01 mg/mL,
phosphoglucose isomerase, 0.01 mg/mL, and phosphomannose isomerase 0.0032 mg/mL. In order to
measure the kinetic parameters, the concentration of M1P was varied from 0 to 600 µM, while the M16
was held constant at 3 µM, or the concentration of M16 was varied from 0 to 60 µM, while M1P was
kept constant at 200 µM.
The phosphoglucomutase activity was measured similarly using Hepes 20 mM, pH 7.5 containing
MgCl2 1 mM, NaCl 150 mM, NADP+ 0.25 mM, BSA 0.1 mg/mL, glucose-6-phosphate dehydrogenase
0.01 mg/mL, G1P 100 µM, and G16 100 µM as the activator.
4.3. Thermal Stability
The melting temperatures of thepure proteins (0.6 mg/mL) were measured by thermal shift assay
conducted with the StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), as
already described [52]. Briefly, the experiment was conducted in Hepes 20 mM pH 7.5, containing
MgCl2 1 mM, NaCl 150 mM, dithiothreitol 1 mM, and Sypro Orange 2.4×, and the samples were
heated from 20 to 90◦ at 1 ◦C/min, with increments of 0.6 ◦C.
The long-term stability of wt-PMM2, Val129Met-PMM2, and V231M-PMM2 was monitored at
40 ◦C. The pure proteins (0.03 mg/mL in Hepes 20 mM pH 7.5, containing MgCl2 1 mM, NaCl 150 mM,
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and BSA 0.1 mg/mL) were incubated and the aliquots were taken out at suitable time intervals,
cooled on ice, and the residual phosphoglucomutase activity was measured. Another experiment was
conducted in parallel, in the presence of G16 200 µM.
4.4. Miscellaneous
The protein concentrations were routinely estimated using the Quick Start Bradford (Bio-Rad,
Hercules, CA, USA), with BSA as the standard [53]. SDS-PAGE was performed using standard
procedures [54].
The data concerning the number of observed and predicted synonymous, missense, and loss
of function mutations were extracted from the supplementary Table 13 in the literature [24]. The
disease genes are those annotated in UniProt with the keyword “disease”. The genes associated
with the diseases with a dominant inheritance were obtained from the supplementary File S2 in the
literature [25]. The disease genes present in supplementary Table 13 in the literature [24], minus those
with dominant inheritance, constitute the set that is the object of the analysis (3125 genes).
To explore the distribution of the ratios between the observed and predicted cases for the three
mutation types (MIS—missense, LOF—loss of function, and SYN—synonymous), we calculated a
five-points distribution range (the lowest datum still within 1.5 IQR of the lower quartile, first quartile,
median, second quartile, and the highest datum still within 1.5 IQR of the upper quartile) using the
function boxplot() from the R graphics package [55]. We then plotted the observed/predicted ratio
for each one of the 3125 genes contained in the file, with respect to the mutation class (MIS, LOF, and
SYN), scattering them using a random x-jitter (±2) to improve the information display. We associated
the specific colors to PMM2 (red), CDG1-associated genes (yellow), and CDG2-associated genes (blue).
On top of the point-based visualization, we overlaid the five-point distribution range.
The data concerning the allelic frequencies in the CDG-I genes were extracted from the
literature [26], excluding variants whose consequences are in a non-canonical transcript.
The active site residues were identified with DrosteP [56] on the model PMM2 in closed
conformation [21]. The figure describing the structure of PMM2 and the location of Val129 and
Val231 was prepared with CHIMERA [57].
The deleteriousness predictions of PolyPhen2 [28], SIFT [29], LRT [30], MutationAssessor [31],
PROVEAN [32], metaSVM [33], metaLR [33], MutationTaster [34], FATHMM [35], fathmm-MKL
coding [36], and CADD [37] were obtained running wANNOVAR [58]. The details about the categorical
prediction can be found in ANNOVAR users’ guide [59].
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/8/
2218/s1
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